600285 羚锐制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)15.03521.27019.26815.74814.390
总资产报酬率 ROA (%)8.70812.46311.4369.9729.611
投入资产回报率 ROIC (%)13.94919.20417.40314.64313.178

边际利润分析
销售毛利率 (%)76.04273.29372.28074.27276.908
营业利润率 (%)25.01119.81917.22716.15015.744
息税前利润/营业总收入 (%)24.48118.66016.33814.96314.965
净利润/营业总收入 (%)21.67417.15615.50113.45813.913

收益指标分析
经营活动净收益/利润总额(%)94.19096.19180.73896.01491.646
价值变动净收益/利润总额(%)3.2113.10512.4917.40311.300
营业外收支净额/利润总额(%)0.497-0.500-0.017-5.240-0.794

偿债能力分析
流动比率 (X)1.0831.3681.4651.4821.797
速动比率 (X)0.8561.1221.1811.1841.487
资产负债率 (%)42.49141.35141.11439.72432.842
带息债务/全部投入资本 (%)2.5997.0437.4156.539--
股东权益/带息债务 (%)3,661.2991,286.2061,213.3341,387.0565,320.449
股东权益/负债合计 (%)134.959141.446142.802151.232203.656
利息保障倍数 (X)-37.395-17.595-18.446-39.001-22.819

营运能力分析
应收账款周转天数 (天)26.88324.69822.11921.2930.000
存货周转天数 (天)178.665194.120197.887197.3530.000